Exelixis：FDA的延迟成本低于市场预期（纳斯达克：EXEL）
· seekingalpha.com
FDA将Exelixis的zanzalintinib审查延长了三个月，但未披露任何新的临床失败或安全信号。阅读为什么EXEL股票值得买入。
I do not like seeing the words "major amendment" in an FDA filing. They can describe a manageable request for more information, but they can also be the first p...